Unternehmensübersicht
Cibus, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it develops and licenses gene-edited plant traits to support agricultural productivity. The company's core business model involves creating products that enable farmers to achieve higher yields while simultaneously reducing the reliance on chemical inputs such as fungicides, insecticides, and fertilizers, thereby offering sustainable ingredients for various applications. As of the latest reporting period, the firm employs a workforce of 118 individuals and maintains a total market capitalization of $118.39M. With an annual revenue of $3.64M, these financial metrics indicate that Cibus operates as a small-cap entity with a relatively modest revenue base compared to large-scale pharmaceutical or agricultural conglomerates. The valuation suggests the market places a significant premium on its intellectual property and growth potential, as evidenced by a price-to-sales ratio of 32.53, which is characteristic of early-stage biotechnology companies where future licensing opportunities outweigh current cash flows.
Finanzielle Gesundheit
The company reported a revenue of $3.64M over the trailing twelve months, yet it posted a net income of -$127,085,000, revealing a stark disparity between top-line generation and profitability that highlights an aggressive cost structure or substantial one-time expenses impacting the bottom line. EBITDA stands at -$61,541,000, indicating that even before interest, taxes, depreciation, and amortization, the operational activities are currently generating negative cash conversion before financing costs. Free cash flow is reported at -$51,790,624, which signifies that the company is burning cash and lacks the immediate financial flexibility to fund operations without external capital injections or asset monetization. The gross margin is listed at 100.0%, a figure typical for biotechnology firms that derive revenue primarily from licensing agreements with no direct cost of goods sold, whereas the operating margin of -1273.3% and profit margin of 0.0% underscore severe operational inefficiencies or heavy investment in research and development relative to current sales. The balance sheet presents a highly leveraged profile with total debt of $267.96M against only $9.92M in cash, resulting in a debt-to-equity ratio of 1227.56, which implies the company relies heavily on creditor financing rather than equity buffers. Liquidity is constrained further by a current ratio of 0.72, indicating that current assets are insufficient to cover current liabilities without relying on debt refinancing or asset sales. Return on Equity stands at -221.0% and return on assets at -12.9%, metrics that reveal management has yet to generate positive returns on the capital invested by shareholders or creditors, reflecting the high-risk nature of the biotechnology development lifecycle.
Bewertungsanalyse
Valuation multiples for Cibus reflect the challenges of applying traditional metrics to a loss-making biotechnology firm, as the trailing P/E ratio is N/A due to negative earnings, while the forward P/E is calculated at -7.33, suggesting the market anticipates continued negative earnings in the near term or is pricing in significant future losses. The price-to-book ratio of 3.64 indicates that the market values the company at a premium of 3.64 times its book value, a common scenario for biotech firms where intangible assets like patents and intellectual property are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 32.53 and an EV/EBITDA of -5.84 further illustrate that investors are willing to pay a high multiple for revenue growth potential despite the absence of current profitability. Regarding trading range, the 52-week high is $4.19 and the 52-week low is $1.09, meaning the current share price is fluctuating within this established volatility band. The stock exhibits a beta of 1.93, which quantifies that the stock's price volatility is nearly double that of the broader market, indicating high sensitivity to market sentiment and sector-specific news.
Growth & Income
The company's revenue growth year-over-year is -12.8%, while earnings growth is N/A due to the lack of positive earnings, implying that the business is currently contracting in terms of top-line sales and has not yet achieved sustainable profitability to support growth calculations. As a non-dividend payer, Cibus does not distribute any cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm retains all available cash flow to fund its operations and research initiatives rather than distributing income. This reinvestment strategy is typical for biotechnology companies in the development phase, where capital is directed toward advancing clinical trials or securing regulatory approvals rather than rewarding investors with dividends. The overall growth and income profile is characterized by negative revenue expansion, negative cash conversion, and an absence of dividend income, presenting a high-risk, high-reward scenario dependent on the successful commercialization of its gene-edited plant traits.